Metagen Therapeutics adds $1.9M in Series B extension, lifting total to US$54.9M
What's the deal? Metagen Therapeutics, a Japanese biotech developing medicine based on gut bacteria research, has raised US$2.31M in a Series B extension. Impact and ESG investor GLIN Impact CapitalDealroom has a profile for this one. Try Dealroom → backed the round via third-party allotment. The second close brings the full extension round to US$3.77M.
The details: The raise pushes Metagen's cumulative funding to US$54.9M, a figure that includes grants from Japan's medical research agency AMEDDealroom has a profile for this one. Try Dealroom → and NEDODealroom has a profile for this one. Try Dealroom →. Prior rounds span a US$1.77M pre-Series A, a US$13.1M Series A, and a US$27.1M Series B.
What's the endgame? The Tsuruoka-based company, spun out of JuntendoDealroom has a profile for this one. Try Dealroom →, KeioDealroom has a profile for this one. Try Dealroom →, and Institute of Science TokyoDealroom has a profile for this one. Try Dealroom →, is building fecal microbiota transplantation (FMT) as a treatment option for ulcerative colitis, cancer, and Parkinson's disease. It runs "MGT-006," an oral FMT drug for ulcerative colitis, through Phase 1 and Phase 2 trials in Japan and the US.
Where the money goes: Funds will accelerate clinical development of Metagen's FMT drugs and medical technologies. They will also strengthen its supply chain — from donor recruitment to drug manufacturing — anchored by "Tsuruoka Kenben Room," which it calls Japan's first stool donation facility.
Why GLIN? The investor cited the "clear unmet medical needs" in conditions such as ulcerative colitis, where no curative therapy exists. GLIN also plans to help Metagen build systems to measure and manage social impact.
Chief executive officer Taku Nakahara framed the model as citizen-participation medicine. The goal, he said, is to establish stool donation "as a new form of social contribution following blood and bone marrow donation" (translated from Japanese).
The signal: The round reflects rising investor appetite for microbiome therapeutics that pair commercial upside with measurable social value. By turning a discarded resource into a medical supply chain, Metagen is testing whether impact capital can underwrite a novel treatment class — and carry Japan's gut-bacteria medicine to patients abroad.
Image credit: Generated with Gemini
